प्राथमिक स्रोत रिकॉर्ड
निर्णायकटॉपलाइन परिणाम
EYPT: wet AMD में DURAVYU के लिए LUGANO Phase 3 टॉपलाइन डेटा
LUGANO topline showed DURAVYU did not meet the pre-specified non-inferiority endpoint for BCVA change versus aflibercept in the full dataset, although a nominal p-value of 0.0096 was achieved after excluding an asymmetric cohort of 9 patients who lost ≥15 letters from non-wet AMD causes. The company still plans to submit an NDA for wet AMD in the first half of 2027 and expects the LUCIA Phase 3 readout in Q4 2026.
मुख्य तथ्य
- फाइल किया गया
- 10 सित॰ 2026, 11:05 am
- घटना
- टॉपलाइन परिणाम
- दिशा
- नकारात्मक
- कंपनी
EYPTEyePoint- संपत्ति
- vorolanib
- स्रोत
- SEC 8-K
- विश्वसनीयता
- स्रोत सहित
- enrollment time
- five months
- enrolled patients
- over 480
स्रोत का अंश
EX-99.1 2 eypt-ex99_1.htm EX-99.1 LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses | September 2026 Exhibit 99.1 Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, are forward-looking statements, including but not limited to statements regarding: our expectations regarding our clinical development and regulatory plans, including the submission of a potential FDA New Drug Application for DURAVYU™ for the potential treatment of wet AMD
इस संपत्ति पर और
उल्लेखनीय
30 जुल॰ 2026
11:00 am
EYPTEyePointआईपॉइंट ने डीएमई के लिए ड्यूराव्यू के चरण 3 कॉमो और कैपरी परीक्षणों का नामांकन पूरा किया
उल्लेखनीय
13 अप्रैल 2026
08:05 pm
EYPTEyePointEyePoint: DURAVYU चरण 3 समयरेखाएं अप्रैल 2026 निवेशक डेक में अद्यतन की गईं
उल्लेखनीय
2 मार्च 2026
12:05 pm
EYPTEyePointEyePoint ने DME में DURAVYU के लिए Phase 3 COMO और CAPRI परीक्षण शुरू किए